Alnylam Pharmaceuticals | ALNY - Zahlungsmittel Und Äquivalente

Aktienkurs
314.80
Täglich Wechseln
-5.62 -1.75%
Monatlich
-7.24%
Jährlich
24.21%
Q1 Prognose
303.95




Zahlungsmittel Und Äquivalente Veränderung Datum
Acadia Pharmaceuticals USD 819.69M 27.33M 2025-12
Agios Pharmaceuticals USD 89.13M 3.58M 2025-12
Alnylam Pharmaceuticals USD 1.66B 167M 2025-12
Amgen USD 9.13B 316M 2025-12
Arrowhead Research USD 201.64M 112.94M 2025-12
BioCryst Pharmaceuticals USD 335.91M 251.83M 2025-12
BioMarin Pharmaceutical USD 1.31B 61.57M 2025-12
Incyte USD 3.58B 650.78M 2025-12
Ionis Pharmaceuticals USD 2.68B 437M 2025-12
Moderna USD 2.6B 1.46B 2025-12
Neurocrine Biosciences USD 713M 372.8M 2025-12
Novartis USD 9.56B 2.9B 2025-09
PTC Therapeutics USD 984.65M 312.03M 2025-12
Regeneron Pharmaceuticals USD 18.87B 16.36B 2025-12
Sangamo BioSciences USD 38.34M 13.16M 2025-06
Sanofi EUR 7.66B 1.25B 2025-12
Sarepta Therapeutics USD 801.28M 188.2M 2025-12
Takeda JPY 654.94B 26.55B 2025-12
Tectonic Therapeutic USD 253.8M 14.64M 2025-12
Ultragenyx Pharmaceutical USD 202.51M 36.4M 2025-09
Vertex Pharmaceuticals USD 6.61B 321.1M 2025-12
Xencor USD 54.07M 25.78M 2025-12